Clinical trials: Plasma Cell Tumor
High Risk Smoldering Multiple Myeloma (HR-SMM)
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
This study is researching an experimental drug called linvoseltamab (also called "study drug") compared to another drug called daratumumab, in participants with Smoldering Multiple Myeloma (SMM), who are at a High Risk (HR) of…
- Trial name
- LINKER-SMM2 (NCT07393282)
- Testing
- Linvoseltamab, Daratumumab
- Where
- 27 sites in United States, Japan and 3 more
- Volunteers
- 270 people
- Sponsor
- Regeneron Pharmaceuticals
Follicular Lymphoma, Small Lymphocytic Lymphoma
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas
The primary objective will be to assess the overall response rate and to evaluate the efficacy and safety of idelalisib (IDELA; GS-1101) in participants with previously treated indolent Non-Hodgkin Lymphoma (iNHL) that is…
- Conditions
- Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma
- Trial name
- DELTA (NCT01282424)
- Testing
- Idelalisib
- Where
- 41 sites in United States, France and 4 more
- Volunteers
- 125 people
- Sponsor
- Gilead Sciences
Cancer
Clinical Study of Pan-cancer DNA Methylation Test in Plasma
We intend to establish an efficient method for plasma cfDNA extraction and Bisulfite transformation to facilitate the detection of DNA methylation status using multiplex fluorescence PCR.
- Trial name
- NCT05685524
- Testing
- DNA methylation test
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Wuhan Ammunition Life-tech Co., Ltd
Relapsed or Refractory Multiple Myeloma
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Compare efficacy of 56 mg/m2 carfilzomib administered once-weekly in combination with lenalidomide and dexamethasone (KRd 56 mg/m2) to 27 mg/m2 carfilzomib administered twice-weekly in combination with lenalidomide and…
- Trial name
- ARROW2 (NCT03859427)
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- 108 sites in United States, Austria and 15 more
- Volunteers
- 454 people
- Sponsor
- Amgen
Multiple Myeloma, Waldenstrom Macroglobulinemia
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
The purpose of this study is to determine the maximum tolerated dose (MTD), activity, and safety of oprozomib in patients with hematologic malignancies.
- Trial name
- NCT01416428
- Testing
- oprozomib
- Where
- 19 sites in United States
- Volunteers
- 210 people
- Sponsor
- Amgen
Multiple Myeloma
Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year
CC5013-MM024 is a multicenter, open-label, Extended Access Program (EAP) of lenalidomide plus low dose dexamethasone regimen in Chinese subjects with relapsed or refractory MM who participated in Study CC-5013-MM-021.
- Trial name
- NCT02348528
- Testing
- Lenalidomide, Dexamethasone
- Where
- 11 sites in China
- Volunteers
- 65 people
- Sponsor
- Celgene
Waldenström Macroglobulinemia
A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies
This is a multicenter expanded access study of zanubrutinib monotherapy for participants with B-cell malignancies who are ineligible to enroll into any available zanubrutinib clinical trials
- Trial name
- NCT04052854
- Testing
- Zanubrutinib
- Where
- 10 sites in United States
- Sponsor
- BeiGene
Multiple Myeloma, Relapsed Hematologic Malignancy
PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
This study will evaluate the feasibility of a digital health coaching program for adults with relapsed or refractory multiple myeloma (R/R MM). One hundred adults with R/R MM will be enrolled at The University of Washington.
- Trial name
- NCT05956457
- Testing
- Digital Health Coaching Program, Fitbit
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Pack Health
Multiple Myeloma
Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with bortezomib and bortezomib alone in subjects with relapsed or refractory multiple myeloma (MM).
- Trial name
- NCT00315757
- Testing
- Mapatumumab, Bortezomib
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 105 people
- Sponsor
- Human Genome Sciences Inc.
Multiple Myeloma
BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CS1 cCAR in patients with relapsed and/or refractory multiple myeloma.
- Trial name
- NCT04156269
- Testing
- BCMA-CS1 cCAR T cells
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- iCell Gene Therapeutics
Multiple Myeloma
Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma
The primary objective is to compare the time to progression (TTP) of three daily doses of thalidomide (100, 200 and 400 mg) with high-dose dexamethasone in relapsed refractory multiple myeloma (MM) patients and to subsequently…
- Trial name
- OPTIMUM (NCT00452569)
- Testing
- Thalidomide, Dexamethasone
- Where
- 86 sites in Bulgaria, Croatia and 13 more
- Volunteers
- 499 people
- Sponsor
- Celgene
Waldenstrom Macroglobulinemia, Multiple Myeloma
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic…
- Conditions
- Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- CLOVER-WaM (NCT02952508)
- Testing
- Iopofosine I 131 single dose, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose
- Where
- 52 sites in United States, Australia and 9 more
- Volunteers
- 120 people
- Sponsor
- Cellectar Biosciences, Inc.
Multiple Myeloma
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
The purpose of this study is to assess the safety of teclistamab in routine clinical practice when given as monotherapy in Indian participants with relapsed and refractory multiple myeloma (RRMM) (that is, a blood cancer that…
- Trial name
- NCT07030517
- Testing
- Teclistamab
- Where
- 12 sites in India
- Volunteers
- 75 people
- Sponsor
- Johnson & Johnson Private Limited
Multiple Myeloma
Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma
At BMS, we work with physicians/investigators to make investigational products available to patients with life-threatening diseases that have exhausted other treatment options and where there is a reasonable expectation of…
- Trial name
- NCT03126617
- Testing
- Elotuzumab
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
This is a Phase I, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SHR-3836 in patients with multiple myeloma (MM).
- Trial name
- NCT07490613
- Testing
- SHR-3836 administered as multiple doses.
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Hematological Malignancies
Study of IV CBL0137 in Previously Treated Hematological Subjects
This clinical trial is a Phase 1, open-label, sequential-group, dose-escalation (Part 1) and cohort-expansion study (Part 2) evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of intravenously (IV)…
- Trial name
- NCT02931110
- Testing
- CBL0137
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Incuron
Multiple Myeloma
Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma
The objective of this study is to provide early access to daratumumab treatment and collect additional safety data while the medication is not commercially available or available through another protocol for subjects with…
- Trial name
- NCT02477891
- Testing
- Daratumumab
- Where
- 79 sites in United States, Brazil and 4 more
- Sponsor
- Janssen Research & Development, LLC
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
The purpose of this study is to determine the maximum tolerated dose (MTD) of TAK-901 in subjects with advanced hematological malignancies, and to further assess the safety and tolerability of TAK-901 at or below the MTD in an…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT00807677
- Testing
- TAK-901
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma
A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects
TQB2934 is an anti-CD3(Early T Cell Marker)×BCMA (B cell maturation antigen) double-specific antibody，and the isoform is IgG1 (Native Immunoglobulin G1), which at one end binds to the CD3 receptor on the surface of T cells ,and…
- Trial name
- NCT05646758
- Testing
- TQB2934 injection
- Where
- 7 sites in China
- Volunteers
- 140 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Remission
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
Determine the safety and tolerability of POL6326 when used as a single mobilization agent.
- Conditions
- Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Remission, Chronic Myelogenous Leukemia (CML), Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease (HD) in 2nd or Greater Complete Remission, Partial Remission
- Trial name
- NCT01413568
- Testing
- POL6326, Leukapheresis, PBSC Transplant
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Polyphor Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.